ARE EXISTING REGULATORY EVIDENCE STANDARDS ADEQUATE FOR INFORMING DECISIONS ON MEDICAL DEVICE ADOPTION BY U.S. HEALTHCARE PROVIDERS/HOSPITALS?
Author(s)
Moderator: Nicole Ferko, MSc, Value & Evidence Division, Marketing and Market Access, EVERSANA, Burlington, ON, Canada
Panelists: Barbara Strain, MA, CVAHP, Association of Healthcare Value Analysis Professionals (AHVAP), Charlottesville, VA, USA; Gloria Graham, DNP, RN, CVAHP, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; Paul Michael Delatore, MBA, Alcon, Fort Worth, TX, USA
Presentation Documents
ISSUE: With cost containment pressures and the need to optimize health and healthcare delivery, U.S. healthcare providers/hospitals must consider economic value, in addition to clinical evidence and feasibility of adoption, to inform medical device adoption decisions. As the majority of devices do not receive additional reimbursement by payers, providers often need to absorb the costs within operating budgets. Adoption decisions are frequently deliberated by hospital Value Analysis (VA) Committees which evaluate how a device may address a current problem, what evidence exists to demonstrate efficacy and safety, cost, and feasibility of integration to justify adoption. There are no guidelines to inform such evidence development needs, and requirements can vary considerably across institutions. Traditional HEOR methods may be important sources of data; however, hospital decision-makers may not be trained in such methods and may perceive bias in evidence provided by manufacturers. There is a need for clear guidance to consolidate the type of evidence required to support provider decision-making.
OVERVIEW: This panel will debate the evidence requirements for informing VA decisions by setting and device categories, with a focus on medical devices that do not achieve incremental reimbursement.
Nicole Ferko will moderate and provide an introduction to the VA framework (5 minutes). The moderator will pose questions to panelists, allowing each time to respond and debate the issues (40 minutes). Case studies (10 minutes). Audience questions (5 minutes). Barbara Strain will discuss the hospital VA perspective on the utilization and challenges of such evidence for innovative and disruptive technologies and provide suggestions for manufacturers. Gloria Graham will present a different hospital VA perspective through the lens of an academic pediatric medical center. Paul Delatore will represent the manufacturer perspective on what HEOR methods have been successfully used with hospital providers and value analysis and the challenges that evolving evidence requirements and needs pose.Conference/Value in Health Info
Code
IP3
Topic
Health Technology Assessment